| Document |
Document Title |
|
WO/2008/150486A2 |
A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A ...
|
|
WO/2008/148853A1 |
The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: each R1 is independently selected from the group consisting of Cl, Br, CH3 and CF3; X is carbon or nitroge...
|
|
WO/2008/139467A2 |
The present disclosure provides processes for the preparation of lipid conjugated cyclic carbonate derivatives. More specifically, the present disclosure is based on the finding that reacting lipids, such as, ceramides, with N,N'-disucci...
|
|
WO/2008/136378A1 |
Disclosed is a compound represented by the following general formula: (wherein R1 represents a hydrogen atom or the like; R2 represents an optionally substituted alkyl or aryl group or the like; R3 and R4 may be the same or different and...
|
|
WO/2008/134058A1 |
A dechalcogenative method for the preparation of an allylic sulfide comprises contacting an activated chalcogenide of Formula (I) with a thiol of Formula (II) for a period of time sufficient to form an intermediate of Formula (III), and ...
|
|
WO/2008/125342A2 |
The present invention relates to novel vanilloid receptor ligands, a method for the production thereof, pharmaceuticals containing said compounds, and the use of said compounds for the production of pharmaceuticals.
|
|
WO/2008/118935A1 |
Processes and intermediates arc provided for the preparation of substituted aminomethyl 2,3,8,9-tctrahydiO-7H-1.4-dioxino[2.3-e]indo]-8-ones of the Formula (A) wherein the variables n, R and R3 are as described herein. Such compounds are...
|
|
WO/2008/117305A2 |
The present invention provides process for the preparation of novel intermediates of (S)-Pregabalin. The present invention also provides process for the preparation of (S)-Pregabalin or a pharmaceutically acceptable salt or solvate there...
|
|
WO/2008/109601A2 |
The transient response of a switching power supply is improved by providing one or more supplemental power sources connected to the output terminal of the power supply. In one embodiment additional current is provided when a sudden incre...
|
|
WO/2008/105286A1 |
Disclosed is a novel compound, namely a pentacyclic liquid crystal compound having a CF2O bonding group, which has general physical properties necessary for a compound, stability against heat and light, a wide temperature range of a liqu...
|
|
WO/2008/102607A1 |
Disclosed is a method for the purification of a cyclic ester which comprises the steps of: mixing a co-effluent of a cyclic ester produced by the depolymerization with heating of a hydroxycarboxylic acid oligomer in the presence of a dep...
|
|
WO/2008/089461A1 |
Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and inf...
|
|
WO/2008/088487A2 |
Phosphorus-sulfur compounds have flame retardant activity in organic polymer systems. The phosphorus-sulfur compounds can be represented by the structure: Formula (I) wherein X is oxygen or sulfur, T is a covalent bond, oxygen, sulfur or...
|
|
WO/2008/080823A1 |
The present invention relates to methods of reducing ketal acids, salts and esters to form corresponding ketal alcohols. More particularly, the reducing methods convert the ketal acids, salts, or esters to ketal alcohols by using a reduc...
|
|
WO/2008/080822A1 |
The present invention relates to methods of subjecting a mixture of stereoisomers to epimerization and optionally recrystallization procedures to obtain a desired stereoisomer in high yield and purity. Relying upon solubility differences...
|
|
WO/2008/080824A1 |
The present invention advantageously provides ketal functional compounds that can be strong electrophiles under conditions compatible with ketal groups, are stable, crystalline solids at room temperature, and are much safer to handle tha...
|
|
WO/2008/078762A1 |
Disclosed are: a study on the synthesis of a novel N-(2-aminophenyl)benzamide derivative having an urea structure and represented by the general formula (1); and the utilization of the pharmacological activity of the derivative. A compou...
|
|
WO/2008/075165A1 |
An improved synthesis for the preparation of [R-(R*, R*)]-2-(4-fluorophenyl)- β, δ-dihydroxy-5-(1- methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1 H-pyrrole-1-heptanoic acid or a pharmaceutically acceptable salt thereof, as well as o...
|
|
WO/2008/075353A1 |
The present invention relates to sulfonamide derivatives of formula (I) (wherein R1, R2, R3, R3', R4and R5are as defined in the claims), to pharmaceutical compositions comprising the same, and to uses thereof. Compounds of the invention ...
|
|
WO/2008/071776A2 |
The raw material used in m ost process for the production of cyclic diesters of alpha - hydroxiacids, such as Lactide and Glycolide, is a 10% solution of Hydroxyacid. During the evacuation of the solution and condensation reaction water,...
|
|
WO/2008/067911A1 |
The invention relates to new compounds of the formula (I) in which W, X, Y, Z and CKE have the meanings given above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides, an...
|
|
WO/2008/061821A1 |
The present invention relates to a process for preparing tetramethyl glycolide, in which a composition comprising at least 50% by weight of 2-hydroxyisobutyric acid and/or tetramethyl glycolide is heated to a temperature of at least 100°C.
|
|
WO/2008/061871A1 |
The present invention relates to ketomethionine ketals or hemiketals and their derivatives and also their preparation and their use as fodder additives, in particular for the nutrition of ruminants.
|
|
WO/2008/058402A1 |
The invention is directed to compounds and methods for treating protein folder disorders. In certain embodiments the invention provides compounds and methods for treating neurodegenerative diseases such as Alzheimer's disease, tauopathy,...
|
|
WO/2008/052086A1 |
Compounds are described herein which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds have the formula I: or pharmaceutically acceptable salts thereof, wherein each of A, R1, R2, R3, R4, Ra, ...
|
|
WO/2008/047651A1 |
Disclosed is a process for producing flake-like dried DOG. In the process, DOG having a liquid content of 10 to 50 mass% is subjected to a continuous melting/drying step under specific conditions. The resulting product is subjected to a ...
|
|
WO/2008/043947A1 |
The invention relates to a method for the synthesis of cyclic acetals that comprises reacting at least one carbonyl-function compound selected from aldehydes, ketones and/or linear acetals, on a polyol in a concentrated aqueous solution ...
|
|
WO/2008/031157A1 |
The present invention relates to a class of acetylenic compounds, to a method of preparing the acetylenic compounds, and to the polymerisation and therapeutic uses of the acetylenic compounds. The invention particularly relates to compou...
|
|
WO2006024627A9 |
The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1, 2, 3, or 4; Z represents O, S, NR6, SO or SO2; R1 represent hydrogen, cyano, hydroxy, or C1-4alkyl optiona...
|
|
WO/2008/016199A1 |
The present invention relates to a process for the preparation of chiral 2-hydroxymethyl-l,4-benzodioxane compound. The method in accordance with the present invention comprises the steps of reacting chiral epihalohydrin or chiral glycid...
|
|
WO/2008/015885A1 |
Disclosed is a method for purifying a hydroxycarboxylic acid by distillation, which is characterized by distilling an aqueous hydroxycarboxylic acid solution containing a high boiling point hydroxy compound which is composed of at least ...
|
|
WO/2008/011742A1 |
A method of using organic compounds and providing slow release flavoring in or for food products wherein flavor precursors are added to flavor compositions and/or food products and release flavor compounds upon consumption of the food pr...
|
|
WO/2008/012950A1 |
Disclosed are: a composition useful for the detoxification of a toxic compound containing arsenic or the like efficiently and systematically; and a method for the detoxification of a toxic compound using the composition. Specifically, di...
|
|
WO/2008/013550A1 |
Novel substituted phenylsulfur trifluorides that act as fluorinating agents are disclosed. Also disclosed are methods for their preparation and methods for their use in introducing one or more fluorine atoms into target substrate compounds.
|
|
WO/2008/010455A1 |
Disclosed is a method for producing a β-diaryl electron-withdrawing group substituted compound at high yield with high selectivity. Specifically, an optically active β-diaryl electron-withdrawing group substituted compound represented ...
|
|
WO/2008/007780A1 |
Disclosed is a pentadienamide derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof or the like. (I) wherein R1 represents a substituted or unsubstituted aryl or a substituted or unsubstituted aromatic h...
|
|
WO/2008/006860A2 |
This invention describes the preparation of fatty acid esters of glycerol formal either by a triglyceride transesterification process or, alternatively, by an esterification process of fatty acids previously obtained from the hydrolysis ...
|
|
WO/2007/148975A2 |
The invention relates to a method for the purification or recovery of lactide rich streams by the combination of a suspension-based melt crystallization process with a subsequent separation of the pure lactide crystals in a wash column.
|
|
WO/2007/139062A1 |
[PROBLEMS] To provide a prophylactic and therapeutic agent for obesity which has a more effective and potent efficacy and has reduced adverse side-effects, and also provide a method for prevention and treatment of obesity. [MEANS FOR SOL...
|
|
WO/2007/139998A2 |
The present invention provides methods for preparing a compound of formula D having activity as dopamine autoreceptor agonist and partial agonists at the postsynaptic dopamine D2 receptor. This compound is useful for treating dopaminergi...
|
|
WO/2007/138485A2 |
1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections.
|
|
WO/2007/136790A2 |
Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs.
|
|
WO/2007/133751A2 |
A stabilized semi-solid delivery vehicle contains a polyorthoester and an excipient, and a pharmaceutical composition contains an active agent, optionally a stabilizing agent, and the delivery vehicle. The pharmaceutical composition may ...
|
|
WO/2007/127309A2 |
Provided are processes for the synthesis of 3-isobutylglutaric acid, an intermediate in the synthesis of (S)-Pregabalin.
|
|
WO/2007/123942A2 |
The present invention relates to methods for synthesizing compounds of formula (I) or pharmaceutically acceptable salts thereof: Formula (I) wherein each of R1, R2, R3, R4, x, m, n, and Ar are as defined, and described in classes and sub...
|
|
WO/2007/115968A2 |
Provided is a process for the preparation of 2(R)-(3-chloro-4-methanesulfonyl-phenyl)-3-((R)-3-oxocyclope
ntyl)-N-pyrazin-2-ylpropionamide of formula (I) and its isopropanol solvate as a glucokinase activator which increases insulin secr...
|
|
WO/2007/114213A1 |
[PROBLEMS] To provide a compound capable of inhibiting the production of a prostaglandin or leukotriene. [MEANS FOR SOLVING PROBLEMS] Disclosed is a compound represented by the general formula (I) or a salt thereof: (I) wherein (a) repre...
|
|
WO/2007/107276A2 |
The present invention relates to a process for preparing C7 intermediates and their use in the preparation of pyrrole derivatives of a class that is effective at inhibiting the biosynthesis of cholesterol in humans, and more particularly...
|
|
WO/2007/099553A2 |
The present invention relates to novel 1,3-dioxane carboxylic acids of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods fo...
|
|
WO2007057703B1 |
Process for the preparation of statins, in particular atorvastatin via intermediates of Formula (1) and a process for the preparation of said intermediates.
|
